2022-500903-38-00Active, not recruitingPhase 1
Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular carcinoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Sept 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 25 Aug 2022
- Start date
- 9 Feb 2023
- Lead sponsor
- University Hospital Grenoble
- Diseases
- Liver and biliary tract cancer
- EU CT number
- 2022-500903-38-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 52
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (12)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire D Angers | Angers Cedex 9 | France | Active, not recruiting |
| Centre hospitalier Universitaire de Bordeaux | Bordeaux | France | Active, not recruiting |
| Centre Hospitalier Universitaire De Caen Normandie | Caen Cedex 9 | France | Active, not recruiting |
| Hopital Beaujon | Clichy | France | Active, not recruiting |
| Centre Hospitalier Universitaire Grenoble Alpes | Grenoble Cedex 9 | France | Active, not recruiting |
| Centre Leon Berard | Lyon | France | Active, not recruiting |
| Hôpital Saint Joseph | Marseille | France | Active, not recruiting |
| Centre Hospitalier Universitaire de Nantes | Nantes | France | Active, not recruiting |
| Hopital Saint Antoine | Paris Cedex 12 | France | Active, not recruiting |
| Pitie Salpetriere Hospital | Paris Cedex 13 | France | Active, not recruiting |
| Centre Hospitalier Universitaire de Reims | Reims | France | Active, not recruiting |
| Centre Hospitalier Universitaire de Toulouse | Toulouse | France | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.